Skip Navigation LinksHome > June 2014 - Volume 20 - Issue 4 > Successful Management of Refractory Pediatric-Onset Complex...
JCR: Journal of Clinical Rheumatology:
doi: 10.1097/RHU.0000000000000100
Case Reports

Successful Management of Refractory Pediatric-Onset Complex Aphthosis With Lenalidomide

Kalampokis, Ioannis MD, MPH*; Rabinovich, C. Egla MD, MPH

Collapse Box

Abstract

Abstract: Clinicians are frequently confronted with patients presenting with oral aphthous ulcers or orogenital aphthae. Patients with complex aphthosis are characterized by the nearly constant presence of more than 3 oral aphthous ulcers or recurrent orogenital aphthae but do not satisfy the criteria for Behçet disease. We report a severe case of pediatric-onset complex aphthosis with poor response and/or significant toxicity to first-line medications. Lenalidomide, a second-generation immunomodulatory drug, induced a complete disease remission within few days of therapy. The patient has been treated for nearly 3 years with significant subjective and clinical improvement and no adverse effects. Thereby, lenalidomide may represent a well-tolerated and effective medication for patients with complex aphthosis who are intolerant or not responsive to first-line agents. Nevertheless, in view of the rare but serious potential adverse effects of lenalidomide such as teratogenicity and cancer, a clinical trial is necessary to assess the true risk-to-benefit ratio for the use of lenalidomide in patients with complex aphthosis.

© 2014 by Lippincott Williams & Wilkins, Inc.

Follow Us!

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.